Cargando…

Ustekinumab in the therapy of chronic plaque psoriasis

Psoriasis is a chronic inflammatory disorder characterized by T cell dysregulation and a chronic inflammatory infiltrate within the epidermis. Several cytokines play an important role in the pathogenesis of psoriasis, including interleukin-12 (IL-12) and IL-23. These cytokines act via induction of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Neill, Jenna L, Kalb, Robert E
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726055/ https://www.ncbi.nlm.nih.gov/pubmed/19707405

Ejemplares similares

Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010)

Listeria Meningitis in a Patient With Plaque Psoriasis on Ustekinumab Therapy
por: Roy, Moni, et al.
Publicado: (2022)

Infliximab for the treatment of plaque psoriasis
por: Gall, Jennifer S, et al.
Publicado: (2008)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010)

Plaque psoriasis and morphea in a patient on ustekinumab: A case report
por: Cirone, Katrina, et al.
Publicado: (2023)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea
por: Choi, Chong Won, et al.
Publicado: (2018)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Paradoxical Flare of Psoriasis after Ustekinumab Therapy
por: Lee, Ho Yeol, et al.
Publicado: (2017)

Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
por: Burlando, Martina, et al.
Publicado: (2021)

Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations
por: Yang, Seungkeol, et al.
Publicado: (2021)

Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient
por: Chu, Christopher H., et al.
Publicado: (2017)

Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
por: Burlando, Martina, et al.
Publicado: (2020)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis
por: Schafer, Jeremy A., et al.
Publicado: (2010)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009)

Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab
por: Zhao, Yue, et al.
Publicado: (2014)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
por: Hermanns-Lê, Trinh, et al.
Publicado: (2012)

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis
por: Krulig, Eliana, et al.
Publicado: (2010)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
por: Lynch, Maeve, et al.
Publicado: (2017)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
por: Bagel, Jerry, et al.
Publicado: (2018)

Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial
por: Harris, Kristina M., et al.
Publicado: (2021)

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
por: Diels, J., et al.
Publicado: (2020)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019)

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
por: Asahina, Akihiko, et al.
Publicado: (2023)

The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries
por: Youn, Sang Woong, et al.
Publicado: (2016)

Recalcitrant psoriasis responding to new bilogic drug: Ustekinumab
por: Husein-ElAhmed, Husein, et al.
Publicado: (2013)

Genome-Wide Association Study of Ustekinumab Response in Psoriasis
por: Connell, William T., et al.
Publicado: (2022)

Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab
por: Garcia-Valladares, Ignacio, et al.
Publicado: (2011)

Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
por: Mahé, E., et al.
Publicado: (2022)

Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer
por: Quatresooz, Pascale, et al.
Publicado: (2012)

The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
por: Jenneck, Claudia, et al.
Publicado: (2007)

Influence of ustekinumab on body weight of patients with psoriasis: an initial report
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2014)

Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases
por: Kim, Ye Seul, et al.
Publicado: (2016)

Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis
por: Tonini, Annalisa, et al.
Publicado: (2019)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton, Philip, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oogiivqjufpa8j6p9p9c5a1o8j